Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Kaiser, M; Semeraro, MD; Herrmann, M; Absenger, G; Gerger, A; Renner, W.
Immune Aging and Immunotherapy in Cancer.
Int J Mol Sci. 2021; 22(13): 7016 Doi: 10.3390/ijms22137016 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Führende Autor*innen der Med Uni Graz

Kaiser Melanie

Co-Autor*innen der Med Uni Graz

Absenger Gudrun

Gerger Armin

Herrmann Markus

Renner Wilfried

Semeraro Maria Donatella

Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:

Immune functions decline as we age, while the incidence of cancer rises. The advent of immune checkpoint blockade (ICB) has not only revolutionized cancer therapy, but also spawned great interest in identifying predictive biomarkers, since only one third of patients show treatment response. The aging process extensively affects the adaptive immune system and thus T cells, which are the main target of ICB. In this review, we address age-related changes regarding the adaptive immune system with a focus on T cells and their implication on carcinogenesis and ICB. Differences between senescence, exhaustion, and anergy are defined and current knowledge, treatment strategies, and studies exploring T cell aging as a biomarker for ICB are discussed. Finally, novel approaches to improve immunotherapies and to identify biomarkers of response to ICB are presented and their potential is assessed in a comparative analysis.

Find related publications in this database (Keywords)

T cells

aging

cancer

immune checkpoint inhibitors

biomarker

senescence

exhaustion

© Med Uni Graz • Impressum